Opus Genetics (IRD) EBT (2010 - 2026)

Opus Genetics (IRD) has reported EBT for 17 consecutive years, with -$65.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 699.79% year-over-year to -$65.5 million; the TTM figure through Mar 2026 stood at -$106.9 million (down 82.42% YoY), while the FY2025 annual figure was -$49.6 million, up 13.8% from the prior year.
• EBT slipped to -$65.5 million in Q1 2026 per IRD's latest filing, from -$16.5 million in the prior quarter.
• Across five years, EBT topped out at $34.3 million in Q4 2022 and bottomed at -$65.5 million in Q1 2026.
• Historically, EBT has averaged -$9.7 million across 5 years, with a median of -$7.1 million in 2024.
• Annual changes were most pronounced in 2022 — EBT surged 642.63% — and 2026, when it plunged 699.79%.
• Opus Genetics' EBT stood at $34.3 million in 2022, then plunged by 114.0% to -$4.8 million in 2023, then plunged by 632.44% to -$35.1 million in 2024, then surged by 52.97% to -$16.5 million in 2025, then slumped by 296.63% to -$65.5 million in 2026.
• Business Quant data shows IRD's EBT at -$65.5 million in Q1 2026, -$16.5 million in Q4 2025, and -$17.5 million in Q3 2025.